Pregabalin Add‐on Treatment: A Randomized, Double‐blind, Placebo‐controlled, Dose–Response Study in Adults with Partial Seizures

@article{Arroyo2004PregabalinAT,
  title={Pregabalin Add‐on Treatment: A Randomized, Double‐blind, Placebo‐controlled, Dose–Response Study in Adults with Partial Seizures},
  author={S. Arroyo and H. Anhut and A. Kugler and Caroline M. Lee and L. Knapp and E. Garofalo and Silke-Lo Messmer},
  journal={Epilepsia},
  year={2004},
  volume={45}
}
Summary:  Purpose: To evaluate pregabalin (PGB), 150 mg/day, and PGB, 600 mg/day, as an add‐on treatment for patients with refractory partial seizures concurrently treated with one to three anticonvulsants (AEDs). 
Pregabalin Add‐on Treatment in Patients with Partial Seizures: A Novel Evaluation of Flexible‐dose and Fixed‐dose Treatment in a Double‐blind, Placebo‐controlled Study
TLDR
Evaluated pregabalin as add‐on therapy for patients with partial seizures administered as fixed dose or as flexible dose adjusted to optimal seizure reduction and tolerability. Expand
Adjunctive use of controlled‐release pregabalin in adults with treatment‐resistant partial seizures: A double‐blind, randomized, placebo‐controlled trial
To assess the efficacy and tolerability of add‐on pregabalin controlled‐release formulation (PGB‐CR) (doses of 165 or 330 mg/day) in patients with partial‐onset seizures (POS).
Pregabalin add‐on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: A double‐blind, randomized, placebo‐controlled, multicenter trial
Purpose:  To evaluate the efficacy and safety of pregabalin (PGB) as adjunctive therapy, using a flexible‐dosing schedule in Korean patients with refractory partial‐onset seizures.
Pregabalin in partial seizures: a pragmatic 21‐week, open‐label study (PREPS)
TLDR
Pregabalin has demonstrated efficacy in controlled trials as adjunctive treatment in patients with refractory seizures and is warranted for use in clinical practice. Expand
Long‐term add‐on pregabalin treatment in patients with partial‐onset epilepsy: Pooled analysis of open‐label clinical trials
Purpose:  To evaluate the safety, tolerability, and efficacy of long‐term pregabalin as add‐on therapy for patients with poorly controlled partial seizures.
Efficacy and safety of pregabalin versus levetiracetam as adjunctive therapy in patients with partial seizures: A randomized, double‐blind, noninferiority trial
To assess the comparative efficacy and safety of pregabalin and levetiracetam for the reduction of seizure frequency in patients with partial seizures.
Pregabalin as adjunctive therapy in adult and pediatric patients with generalized tonic‐clonic seizures: A randomized, placebo‐controlled trial
TLDR
This phase 3 study evaluated the efficacy and safety of pregabalin for GTC seizures in adults and children with epilepsy. Expand
Seizure‐Free Outcome in Randomized Add‐on Trials of the New Antiepileptic Drugs
TLDR
This study provides clinically useful, previously unpublished comparative analyses of seizure‐freedom rates for newer antiepileptic drugs (AEDs) and recommends a standard for data presentation and analysis. Expand
Pregabalin adjunctive therapy for focal onset seizures in children 1 month to <4 years of age: A double‐blind, placebo‐controlled, video‐electroencephalographic trial
To evaluate the efficacy and safety of pregabalin as adjunctive treatment for children (aged 1 month‐<4 years) with focal onset seizures (FOS) using video‐electroencephalography (V‐EEG).
Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: A phase 1, randomized controlled study
To evaluate the safety, tolerability, and pharmacokinetics (PK) of pregabalin as adjunctive therapy in children with refractory partial seizures.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Exposure‐response analysis of pregabalin add‐on treatment of patients with refractory partial seizures
TLDR
The exposure‐response relationship of pregabalin add‐on treatment for refractory partial seizures after multiple dosing in patients is described and the factors that influence this relationship are identified. Expand
Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures
TLDR
Adjunctive therapy with pregabalin 150, 300, and 600 mg/d, given in twice-daily doses without titration, is significantly effective and well tolerated in the treatment of patients with partial seizures as demonstrated in patients with refractory partial seizures. Expand
New Antiepileptic Drugs: Comparison of Key Clinical Trials
TLDR
Data accrued from clinical trials of five new antiepileptic drugs are compared for efficacy in reducing seizures and self‐reported adverse events as a basis of selection among new AEDs. Expand
Pregabalin in generalized anxiety disorder: a placebo-controlled trial.
TLDR
Pregabalin is an effective, rapidly acting, and safe treatment for generalized anxiety disorder in short-term treatment and does not appear to have the withdrawal symptoms associated with the benzodiazepines. Expand
Pregabalin (Pfizer).
  • R. Huckle
  • Medicine
  • Current opinion in investigational drugs
  • 2004
Pregabalin is a gamma-aminobutyric acid analog that is under development by Pfizer for the potential treatment of central nervous system disorders, including epilepsy, neuropathic pain, fibromyalgiaExpand
Pregabalin for the treatment of postherpetic neuralgia
TLDR
Treatment of postherpetic neuralgia with pregabalin is safe, efficacious in relieving pain and sleep interference, and associated with greater global improvement than treatment with placebo. Expand
Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine
TLDR
It is demonstrated that prolonged treatment with VPA and CBZ increases plasma concentrations of Hcy and a significant decrease of serum folate and plasma PLP after 1 year of therapy. Expand
Development of the Quality of Life in Epilepsy Inventory for Adolescents: The QOLIE‐AD‐48
TLDR
The development of an instrument to assess health‐related quality of life (HRQOL) in adolescents with epilepsy is reported and it is shown that it can improve the quality of lives of teenagers with epilepsy. Expand
3‐Substituted GABA analogs with central nervous system activity: A review
TLDR
Pregabalin was identified after an investigation into other 3‐substituted GABA analogs and has since been shown to have a similar pharmacological profile to gabapentin with greater potency in preclinical models of pain and epilepsy. Expand
Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)
TLDR
A review of drugs in development and recently marketed AEDs and of a new antiepileptic device, the neurocybernetic prosthesis (NCP), has become available. Expand
...
1
2
3
4
...